Citations

Mayo Clinic

Showing 10 of 108537 citations.

The value of microvascular breast reconstruction: Cost equivalence of TRAM and DIEP flaps implications in the era of CMS reforms
Foppiani, Jose, Kim, Erin , Escobar‐Domingo, Maria J. , Taritsa, Iulianna C., Schuster, Kirsten A. , Ho, Olivia A. , Rinker, Brian, Lee, Bernard T. , Lin, Samuel J. , Foppiani, Jose , Escobar-Domingo, Maria J , Lee, Bernard T , Alvarez, Angelica Hernandez , Lee, Daniela

Microsurgery | May 8, 2024 | Volume: 44 | Issue: 4 | Pages: No page available

10.1002/micr.31185 | PMID 38716656 Get It

AbstractBackgroundRecent CMS billing changes have raised concerns about insurance coverage for deep inferior epigastric perforator (DIEP) flap breast reconstruction. This study compared the costs and utilization of transverse rectus abdominis myocutaneous (TRAM), DIEP, and latissimus dorsi (LD) flaps in breast reconstruction.MethodThe study utilized the National Inpatient Sample database to identify female patients who underwent DIEP, TRAM, and LD flap procedures from 2016 to 2019. Key data such as patient demographics, length of stay, complications, and costs (adjusted to 2021 USD) were analyzed, focusing on differences across the flap types.ResultsA total of 17,770 weighted patient encounters were identified, with the median age being 51. The majority underwent DIEP flaps (73.5%), followed by TRAM (14.2%) and LD (12.1%) flaps. The findings revealed that DIEP and TRAM flaps had a similar length of stay (LOS), while LD flaps typically had a shorter LOS. The total hospital charges to costs using cost‐to‐charge ratio were also comparable between DIEP and TRAM flaps, whereas LD flaps were significantly less expensive. Factors such as income quartile, primary payer of hospitalization, and geographic region significantly influenced flap choice.ConclusionThe study's results appear to contradict the prevailing notion that TRAM flaps are more cost‐effective than DIEP flaps. The total hospital charges to costs using cost‐to‐charge ratio and hospital stays associated with TRAM and DIEP flaps were found to be similar. These findings suggest that changes in the insurance landscape, which may limit the use of DIEP flaps, could undermine patient autonomy while not necessarily reducing healthcare costs. Such policy shifts could favor less costly options like the LD flap, potentially altering the landscape of microvascular breast reconstruction.
Therapeutic biliary stents: applications and opportunities
Ledenko, Matthew , Toskich, Beau , Mehner, Christine , Ceylan, Hakan, Ceylan, Hakan , Patel, Tushar

Expert Review of Medical Devices | May 8, 2024 | Volume: 21 | Issue: 5 | Pages: 399-409

10.1080/17434440.2024.2341960 | PMID 38716580 Get It

Utility of a Third Heplisav-B Dose in Patients With Inflammatory Bowel Disease Without Immunity After 2-Dose Heplisav-B Vaccination
Karime, Christian , Black, Cecily N., Cortés, Pedro , Kwon, Joshua , Caldera, Freddy , Crosby, Sheena , Picco, Michael F., Kinnucan, Jami , Farraye, Francis A. , Kwon, Joshua Y , Crosby, Sheena K , Kinnucan, Jami A., Farraye, Francis A , Caldera, Freddy , Cortés, Pedro , Hashash, Jana G.

American Journal of Gastroenterology | May 8, 2024 | Volume: 119 | Issue: 10 | Pages: 2079-2085

10.14309/ajg.0000000000002863 | PMID 38717045 Get It

INTRODUCTION: Hepatitis B virus (HBV) vaccination is recommended in patients with inflammatory bowel disease (IBD). Although the 2-dose Heplisav-B vaccine has proven effective, more than 20% of patients with IBD do not seroconvert. We prospectively evaluated the effectiveness of a third Heplisav-B dose in patients with IBD lacking HBV immunity despite 2-dose vaccination. METHODS: Adults with IBD who had received 2-dose Heplisav-B vaccination between 2018 and 2023 were identified. Seroconversion was defined as hepatitis B surface antibody (HBsAb) ≥ 10 IU/L measured at ≥4 weeks after vaccination. Patients who did not seroconvert were prospectively offered a third Heplisav-B dose, followed by repeat HBsAb measurement. Demographic, clinical, medication, and vaccination data were compared between those who did and did not seroconvert. RESULTS: Of 192 patients identified, 71.9% (138/192) seroconverted after 2-dose Heplisav-B vaccination. The 54 patients (28.1%) who did not seroconvert were more likely to be male, have diabetes, chronic kidney disease, or elevated Charlson Comorbidity Index. Of the 54 patients, 30 (55.6%) elected to receive a third Heplisav-B dose, with 56.7% (17/30) achieving seroconversion (median HBsAb titer 376 IU/L, IQR 47–1,000 IU/L) despite a median intervaccination time of 416 days (IQR 90.8–667.8). No differences were noted between patients who did vs did not seroconvert after third-dose vaccination. DISCUSSION: In patients with IBD lacking HBV immunity despite 2-dose Heplisav-B vaccination, administration of a third dose resulted in a 56.7% seroconversion rate. Our results suggest that administration of an additional Heplisav-B dose may be an effective strategy in patients lacking immunity despite primary 2-dose vaccination.
Illness intrusiveness, health locus of control, and anxiety symptoms among veterans with congestive heart failure
Priorello, Laura Jean , Arbona, Consuelo , Priorello, Laura

Health Psychology Open | May 8, 2024 | Volume: 11 | Issue: No issue available | Pages: No page available

10.1177/20551029241250311 | PMID 38726462 Get It

Disease severity, illness intrusiveness, and health locus of control (HLC) each contribute to psychosocial wellbeing in patients with congestive heart failure (CHF). To better understand the relationships between these variables regarding anxiety symptoms, we analyzed data from 116 adult male veterans with comorbid CHF and anxiety. Results suggested that illness intrusiveness significantly mediated the relation of CHF severity to anxiety symptom severity, and that the illness intrusiveness domains of physical well-being/diet, work/finances, and other aspects of life (religious/spirituality, community/civic, self-improvement/expression) were also significant mediators of that relationship. The relation of illness intrusiveness to anxiety was not moderated by internal HLC. Findings highlight the importance of assessing and treating various aspects of illness intrusiveness to manage anxiety symptoms in CHF patients.
Gut instinct: Navigating the landscape of parenteral support in short bowel syndrome
Bering, Jamie , Tarleton, Sherry M., DiBaise, John K. , Tarleton, Sherry

Nutrition in Clinical Practice | May 8, 2024 | Volume: 39 | Issue: 5 | Pages: 974-990

10.1002/ncp.11157 | PMID 38715515 Get It

AbstractDepending on the remaining bowel anatomy and the degree of bowel adaptation, patients with short bowel syndrome (SBS) may require parenteral nutrition (PN) and/or intravenous fluid support, sometimes temporarily and sometimes permanently. Although the use of parenteral support in SBS is often lifesaving, it is not without its limitations. Herein, we undertake a focused review of several issues related to use of parenteral support in patients with SBS, including initiation of parenteral support, considerations when formulating PN, select complications, short‐term and long‐term nutrition monitoring, and weaning strategies.
Therapeutic potential and impact of nanoengineered patient‐derived mesenchymal stem cells in a murine resection and recurrence model of human glioblastoma
Al‐kharboosh, Rawan , Bechtle, Alex, Zheng, Jiaying , Mondal, Sujan Kumar , Wilson, David R. , Perez‐Vega, Carlos , Green, Jordan J. , Quiñones‐Hinojosa, Alfredo , Perez-Vega, Carlos, Green, Jordan J , Zheng, Jiaying , Bechtle, Alexandra , Tzeng, Stephany Y.

Bioengineering & Translational Medicine | May 8, 2024 | Volume: 9 | Issue: 6 | Pages: No page available

10.1002/btm2.10675 | PMID 39545093 Get It

Abstract Confounding results of engineered mesenchymal stem cells (MSCs) used as cellular vehicles has plagued technologies whereby success or failure of novel approaches may be dismissed or inaccurately ascribed solely to the biotechnology platform rather than suitability of the human donor. Polymeric materials were screened for non‐viral engineering of MSCs from multiple human donors to deliver bone morphogenic protein‐4 (BMP4), a protein previously investigated in clinical trials for glioblastoma (GBM) to combat a subpopulation of highly invasive and tumorigenic clones. A “smart technology” that target the migratory and stem‐like nature of GBM will require: (1) a cellular vehicle (MSC) which can scavenge and target residual cells left behind after surgical debulking and deliver; (2) anti‐glioma cargo (BMP4). Multiple MSC donors are safely engineered, though varied in susceptibility to accept BMP4 due to intrinsic characteristics revealed by their molecular signatures. Efficiency is compared via secretion, downstream signaling, differentiation, and anti‐proliferative properties across all donors. In a clinically relevant resection and recurrence model of patient‐derived human GBM, we demonstrate that nanoengineered MSCs are not “donor agnostic” and efficacy is influenced by the inherent suitability of the MSC to the cargo. Therefore, donor profiles hold greater influence in determining downstream outcomes than the technical capabilities of the engineering technology.
Building a robust pharmacy research program: Reflections from a large healthcare system not affiliated with a college of pharmacy
Herges, Joseph R. , Wieruszewski, Erin D. , Barreto, Jason N. , Taraba, Jodi L. , Frazee, Erin N. , Oyen, Lance J., Nei, Andrea M. , Wieruszewski, Patrick M. , Thurber, Kristina M., Schramm, Garrett E. , Formea, Christine M. , Rudis, Maria I. , Wieruszewski, Patrick M , Taraba, Jodi L , Wieruszewski, Erin

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | May 7, 2024 | Volume: 7 | Issue: 7 | Pages: 647-658

10.1002/jac5.1957 Get It

AbstractProfessional standards for academic health care system pharmacy departments and clinical pharmacists advocate for research and scholarly activities. Developing and sustaining a research program in a clinical pharmacy department is challenging. Over the span of a decade, a robust pharmacy research program was developed in an academic medical center not affiliated with a college of pharmacy. The aim of this manuscript is to provide a framework suitable for scaling research in pharmacy departments within an academic medical center. Objectives to accomplish the aim includes describing the structure and evolution of the clinical pharmacy department research program, listing measurable outputs and achievements of the pharmacists and the program and describing the barriers encountered and solutions that were enacted to overcome them. Elements critical to building and sustaining a research program in the pharmacy department included long‐term commitment from within the department, a departmental research infrastructure, support from institutional leadership, research funding from the institution, and a growth mindset in accordance with company initiatives to support evolving research needs. A research curriculum was developed for pharmacy residents and pharmacists, created electronic tools for research proposal scientific reviews and allocation of funds, and established departmental research career development awards that allowed for protected time to pursue research and professional development. Over the first 10 years of the program, publication rates grew more than three‐fold, faculty appointments and promotions increased approximately five‐fold, and pharmacist investigators obtained extramural federal funding. Further offsetting clinical workload relative to dedicated research time remains a challenge. The experience and success at this academic medical center suggest it is feasible to develop a robust, sustainable clinical pharmacy department research program.
Optimal Fixation Strategies for Displaced Femoral Neck Fractures in Patients 18–59 Years of Age: An Analysis of 565 Cases Treated at 26 Level 1 Trauma Centers
Roser, Tom, Collinge, Cory A. , Giga, Kashmeera, Lebus, George F., Beltran, Michael J. , Sems, S.A. , Archdeacon, Michael T. , Rodriguez-Buitrago, Andres , Group, the Young Femoral Neck Fracture Working, Crist, Brett D. , Gardner, Michael J. , Sagi, H. Claude , Mir, Hassan Riaz , Mitchell, Phillip M. , Tornetta, Paul , Group, the Young Femoral Neck Fracture Working

Journal of Orthopaedic Trauma | May 7, 2024 | Volume: 38 | Issue: 8 | Pages: 403-409

10.1097/bot.0000000000002828 | PMID 39007655 Get It

OBJECTIVES: The objective of this study was to determine the difference in failure rates of surgical repair for displaced femoral neck fractures in patients younger than 60 years of age according to fixation strategy. METHODS: Design: This is a retrospective, comparative cohort study. Setting: Twenty-six Level 1 North American trauma centers. Patient Selection Criteria: Patients younger than 60 years of age with a displaced femoral neck fracture (OTA 31-B2, B3) undergoing surgical repair from 2005 to 2017. Outcome Measures and Comparisons: Patient demographics, injury characteristics, repair methods used, and treatment failure (nonunion/failed fixation, avascular necrosis, and need for secondary surgery) were compared according to fixation strategy. RESULTS: Five hundred and sixty-five patients met inclusion criteria and were studied. The mean age was 42 years, 36% were female, and the average Pauwels' angle of fractures was 55 degrees. There were 305 patients treated with multiple cannulated screws (MCS) and 260 treated with a fixed-angle (FA) construct. Treatment failures were 46% overall, but was more likely to occur in MCS constructs versus FA devices (55% vs. 36%, P < 0.001). When FA constructs were substratified, the use of a sliding hip screw with addition of a medial femoral neck buttress plate (FNBP) and “antirotation” (AR) screw demonstrated better results than either FNBP or AR screw alone or neither with the lowest overall construct failure rate of 11% (P < 0.036). CONCLUSIONS: Historically used fixation constructs for femoral neck fractures (eg, multiple cannulated screws and sliding hip screw) in young and middle-aged adults performed poorly compared with more recently proposed constructs, including those using a medial femoral neck buttress plate and an antirotation screw. Fixed-angle constructs outperformed multiple cannulated screws overall, and augmentation of fixed-angle constructs with a medial femoral neck buttress plate and antirotation screw improved the likelihood of successful treatment. Surgeons should prioritize fixation decisions when repairing displaced femoral neck fractures in patients. LEVEL OF EVIDENCE: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.
Should All Patients With Stage IE Gastric Mucosa-Associated Lymphoid Tissue Lymphoma Receive Antibiotic Eradication Therapy for Helicobacter pylori ?
Laoruangroj, Chonlada , Habermann, Thomas M. , Wang, Yucai , King, Rebecca L. , Lester, Scott C. , Thompson, Carrie A. , Witzig, Thomas E. , Witzig, T.E. , Lester, Scott , Wang, Yucai , Habermann, Thomas

JCO Oncology Practice | May 7, 2024 | Volume: 20 | Issue: 8 | Pages: 1103-1108

10.1200/op.23.00624 | PMID 38713887 Get It

PURPOSE H. pylori eradication therapy (HPE) can lead to tumor regression in H. pylori–positive (HPP) gastric mucosa-associated lymphoid tissue (MALT) lymphoma. However, some patients do not have detectable H. pylori (HP) infection ( H. pylori–negative [HPN]) and the guidelines differ in their initial approach to HPN patients. The National Comprehensive Cancer Network (NCCN) recommends proceeding to radiation therapy, whereas European Society for Medical Oncology suggests HPE for every patient, even those who are HPN. To address this issue, we evaluated the effectiveness of HPE in limited-stage gastric MALT lymphoma. MATERIALS AND METHODS We retrospectively reviewed patients newly diagnosed with stage IE gastric MALT lymphoma between January 2002 and December 2022. The primary outcome was the complete remission (CR) rate defined as no macroscopic findings of lymphoma and negative gastric biopsy at the follow-up gastric endoscopy. RESULTS Fifty-two patients were reviewed, and HP infection was detected in 19 (36.5%) patients—14 by immunostaining, three by serology, and one each by stool antigen and urea breath test. All 19 HPP and eight of the 33 HPN patients received HPE treatment. The CR rate was 63% (12/19) in HPP patients and 13% (1/8) in HPN patients ( P = .033). After a median follow-up of 89.7 months, only two of the 12 HPP patients achieving CR have relapsed; the one HPN patient who received HPE remains in CR at 12+ months. CONCLUSION For limited-stage HPP gastric MALT lymphoma, HPE is an effective and durable first-line treatment and should be used. For HPN patients, the CR rate with HPE is very low in our experience and is thus in support of the NCCN guideline.